Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutical form: sterile 2R vials containing 10 mg of R2R01.”In the company’s words, NCT05875948 on ClinicalTrials.gov
- Tested for
- Acute Kidney Injury (2 trials), Hepatorenal Syndrome
- Main trialPhase 2
- “This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI”In the company’s words, NCT05875948 on ClinicalTrials.gov
Other drugs for Acute Kidney Injury
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- PrismocitrateVantive Health LLC · Phase 3
- AZD4144AstraZeneca · Phase 2
- LSALT peptideArch Biopartners Inc. · Phase 2
- CSL889CSL Behring · Phase 2
- Allogeneic HB-adMSCsHope Biosciences LLC · Phase 1/2
Coming up1
- 1 Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovStatus changed: Unknown to Recruiting · ClinicalTrials.gov NCT05875948
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2024 | Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome | |
| Phase 2Recruiting | 1 Apr 2027 | Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury | |
| Phase 2Completed | 4 Nov 2024 | To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026